| Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 6.28 | 0.82 | 32.27 | 2.47 |
Op profit growth | -1.96 | 14.27 | 60.85 | -2.03 |
EBIT growth | 4.6 | 14.77 | 32.09 | -4.18 |
Net profit growth | -37.91 | 22.16 | 51.11 | -27.36 |
Profitability ratios (%) | ||||
OPM | 28.57 | 30.98 | 27.33 | 22.47 |
EBIT margin | 23.1 | 23.47 | 20.62 | 20.65 |
Net profit margin | 9.13 | 15.63 | 12.9 | 11.29 |
RoCE | 17.24 | 16.24 | 14.51 | 13.73 |
RoNW | 3.29 | 5.87 | 5.42 | 3.77 |
RoA | 1.7 | 2.7 | 2.27 | 1.87 |
Per share ratios (₹) | ||||
EPS | 45.92 | 73.97 | 60.55 | 40.07 |
Dividend per share | 48 | 35 | 32 | 14 |
Cash EPS | 6.79 | 35.1 | 21.88 | 15.92 |
Book value per share | 351.78 | 344.94 | 285.02 | 273.11 |
Valuation ratios | ||||
P/E | 30.44 | 17.17 | 16.27 | 15.57 |
P/CEPS | 205.7 | 36.19 | 45.04 | 39.18 |
P/B | 3.97 | 3.68 | 3.45 | 2.28 |
EV/EBIDTA | 19.4 | 18.63 | 16.79 | 16.2 |
Payout (%) | ||||
Dividend payout | 0 | 0 | 0 | 34.95 |
Tax payout | -26.23 | -17.97 | -13.64 | -27.16 |
Liquidity ratios | ||||
Debtor days | 67.69 | 72.33 | 66.72 | 67.02 |
Inventory days | 110.33 | 110.1 | 94.57 | 107.19 |
Creditor days | -113.59 | -137.17 | -131.36 | -153.58 |
Leverage ratios | ||||
Interest coverage | -7.7 | -5.32 | -3.63 | -4.01 |
Net debt / equity | 0.61 | 0.73 | 1.06 | 1.21 |
Net debt / op. profit | 1.5 | 1.72 | 2.35 | 4.14 |
Cost breakup (₹) | ||||
Material costs | -28.7 | -26.81 | -27.29 | -27.88 |
Employee costs | -17.94 | -17.98 | -17.99 | -18.91 |
Other costs | -24.78 | -24.21 | -27.37 | -30.72 |
Empagliflozin is a new sodium-glucose co-transporter-2 (SGLT-2) inhibitor approved for glycemic management in individuals with type 2 diabetes.
The USFDA examined Torrent's manufacturing plant in Pithampur during the September quarter and issued a Form 483 with one observation.
The business reported a 13% growth in India revenues to ₹1,632 Crore, driven by outperformance in focus therapies.
When compared to the previous quarter, revenue growth was modest at 1.05%, while net profits experienced a slight decline of 0.88%.
In August, the CDSCO banned more than 156 fixed-dose combination medications from the Indian market.
Here are some of the stocks that may see significant price movement today: Nuvama Wealth, RITES, Torrent Pharmaceuticals, etc.
The company announced that its India business grew by 10% year on year in the June quarter, with sales rising to ₹1,635 Crore from ₹1,426 Crore in Q1 FY24.
Here are some of the stocks that may see significant price movement today: Hindustan Unilever, Bajaj Finance, Vedanta, etc.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
